Project Grant R01AI194372
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,166,933 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center to study Mycobacterium tuberculosis transmission. The project aims to identify bacterial genetic and phenotypic features associated with M. tuberculosis transmission outcomes, including infection, subclinical TB, and clinical TB disease. It will also define M. tuberculosis...
- This $781,369 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The funding supports research to investigate the role of B cells in regulating lung inflammation and disease progression in chronic tuberculosis (TB). The research aims to elucidate how B cells drive CD4+ T cell expansion and pro-inflammatory responses, as well as how B cells may restrict...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- This Project Grant award, titled "Transmission Links and Clinical Spectrum of Exhaled Mycobacterium Tuberculosis", is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The $1,032,233 grant aims to investigate the role of sputum-negative, Mycobacterium tuberculosis (MTB) breath-positive individuals in disease transmission and characterize their underlying clinical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,640,492 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine to study the role of the ESX5 secretome of Mycobacterium tuberculosis in TB and TB-HIV pathogenesis and immunity. The researchers generated a genetic deletion of the ESX5 locus, which they found produced a live attenuated vaccine that is highly effective at preventing TB in...
- The federal Project Grant award of $3,089,360 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and evaluation of innovative tuberculosis (TB) diagnostic platforms and assays. The 5-year project, awarded to Rutgers, The State University of New Jersey, aims to accelerate promising TB diagnostics through a fast-paced pipeline that includes technology scouting, development...
- This $1,173,748.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research on the role of asymptomatic tuberculosis (TB) in disease transmission. The research aims to improve understanding of when individuals become infectious and where transmission is occurring, particularly in community settings outside of household contacts. Key areas of focus include characterizing...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $742,499 Project Grant to the University of Alabama at Birmingham (UAB) for the "Molecular Investigation of Siderophore Secretion and Drug Efflux by Mycobacterium Tuberculosis" research project. This 5-year project, running from August 2025 to July 2030, aims to shed light on the unique siderophore secretion system in Mycobacterium...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,041,944 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rutgers, The State University of New Jersey. The grant will support research to understand the mechanisms underlying heterogeneous transmission of Mycobacterium tuberculosis (MTB) strains, as well as the immune responses of individuals who resist MTB infection despite exposure. The research aims to identify potential targets for host-directed therapies and preventive vaccines to halt tuberculosis transmission. Key activities will include characterizing the in vivo and in vitro immunological and metabolic responses to distinct MTB strains, and investigating the mechanisms behind "resister" phenotypes in exposed household contacts. This 5-year project seeks to advance scientific understanding of TB transmission dynamics and host immunity, with the goal of developing new interventions to interrupt the TB infection cycle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 9/11/25 |